Long-term outcomes and treatment needs in patients with Polypoidal Choroidal Vasculopathy
To Determine Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy(PCV)
Singapore National Eye Centre · NCT03929731
This study looks at how people with Polypoidal Choroidal Vasculopathy are doing five years after their diagnosis to see if early treatment helps their vision and if the disease affects their other eye.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 72 (estimated) |
| Sex | All |
| Sponsor | Singapore National Eye Centre (other gov) |
| Locations | 3 sites (Singapore and 2 other locations) |
| Trial ID | NCT03929731 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term outcomes, recurrence rates, and treatment needs of patients diagnosed with Polypoidal Choroidal Vasculopathy (PCV) five years after their initial presentation. Participants will be contacted for a follow-up examination approximately six years after completing one of three randomized controlled trials related to PCV. The study will evaluate whether early polyp closure is linked to better visual outcomes and will also investigate the risk of disease development in the fellow eye. Data collected will include demographic information, medical history, and treatment details.
Who should consider this trial
Good fit: Ideal candidates are individuals who have previously participated in the EVEREST II, PLANET, or PCV Treat and Extend studies.
Not a fit: Patients who have not participated in the specified prior randomized controlled trials will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term management and treatment strategies for patients with PCV.
How similar studies have performed: Other studies on PCV have shown promising results, indicating that this approach builds on existing knowledge rather than being entirely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T\&E studies * Are able to give consent for this follow up study Exclusion Criteria: * No exclusion criteria unless they do not meet the inclusion criteria
Where this trial is running
Singapore and 2 other locations
- Singapore National Eye Centre — Singapore, Singapore (RECRUITING)
- Tan Tock Seng Hospital — Singapore, Singapore (RECRUITING)
- National University Hospital — Singapore, Singapore (RECRUITING)
Study contacts
- Principal investigator: Principal Investigator — Singapore National Eye Centre
- Study coordinator: Principal Investigator
- Email: gemmy.cheung.c.m@singhealth.com.sg
- Phone: 63227460
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Polypoidal Choroidal Vasculopathy